Prognostic Index for Survival in Patients After Treatment for Primary Hepatocellular Carcinoma

Kogo, Mari; Kano, Ayuko; Kiuchi, Yuji; Mitamura, Keiji; Yoneyama, Keiichiro

doi:10.1007/s10620-006-9137-x

Cited by 7 publications

(5 citation statements)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the 2 groups could be defined as high-risk and low-risk, respectively. The PI has been reported to be useful for predicting prognosis in other studies [27,28,29]. The prediction of prognosis using the PI is thought to be more reliable than that using an individual factor, and, furthermore, we obtained a significant correlation curve between PI values and survival time.…”

Section: Discussionsupporting

confidence: 67%

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

Kogo

Sunaga²,

Nakamura³

et al. 2017

Chemotherapy

Self Cite

View full text Add to dashboard Cite

We retrospectively evaluated clinical data from patients with advanced non-small-cell lung cancer(NSCLC) treated with third-generation chemotherapy agents prior to treatment, to determine a reliable method for predicting prognosis in such patients. We analyzed 100 patients who received third-generation agents (paclitaxel, docetaxel, gemcitabine, irinotecan, and vinorelbine) for the treatment of advanced NSCLC. Factors significantly related to prognosis were evaluated using the Cox regression model, and the prognostic index (PI) was determined by combining these factors. The mean follow-up duration was 12.6 months (0.2-67.0 months). Multivariate analysis identified pleural effusion, absolute neutrophil count (ANC), and C-reactive protein (CRP) level as significant factors that independently contribute to prognosis in patients with advanced NSCLC treated with third-generation agents (p < 0.05). The PI was calculated using these 3 factors, according to the following formula: PI = 0.581 × pleural effusion + 0.125 × ANC + 0.105 × CRP. The death rate in the group with the highest PI scores was significantly higher than in the group with the lowest scores (p < 0.001). Pleural effusion, ANC, and CRP level were the most important factors that contributed to prognosis following chemotherapy with third-generation agents in patients with advanced NSCLC. The PI is suggested to be an appropriate index to predict the prognosis of patients with NSCLC.

show abstract

Section: Discussionsupporting

confidence: 67%

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

Kogo

Sunaga²,

Nakamura³

et al. 2017

Chemotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, in the US, where there is no national screening program, the majority of HCC patients present at an advanced phase of their disease, either due to the severity of the underlying cirrhosis or the extent of their HCC. There has not so far, to our knowledge, been a large prospective study of these advanced unresectable HCC patients; although, several small series having evaluated prognostic factors in these patients [8,20,[24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study

2009

View full text Add to dashboard Cite

Objectives 967 patients with unresectable and untransplantable, biopsy-proven hepatocellular carcinoma (HCC) were prospectively evaluated at baseline and followed up till death. Survival was the end point. Results We found that male gender, ascites, cirrhosis, portal vein thrombosis (PVT), elevated AFP or bilirubin, or alkaline phosphatase, were each statistically significant adverse prognostic factors. Patients with normal AFP survived longer than those with elevated AFP, even in the presence of PVT, large or bilobar tumors or cirrhosis. We used a bivariate analysis to separate patient sub groups based on liver function and tumor characteristics and found clear discrimination in survival between subsets; in addition both cirrhosis and presence of PVT were significant factors. We also used a purely mathematical approach to derive subgroups and a prognostic model for individual patients. Interestingly, the two approaches gave similar predictive information, which opens the possibility of a more detailed mathematical analysis in the future. The results of this large dataset show that amongst non-surgical HCC patients, there are clear subsets with longer survival. Conclusion The data supports the concept of heterogeneity of HCC. The three factors, bilirubin, AFP, and PVT predominate in prognosis.

show abstract

“…However, in the US, where there is no national screening program, the majority of HCC patients present at an advanced phase of their disease, either due to the severity of the underlying cirrhosis or due to the extent of their HCC. There has not so far, to our knowledge, been a large prospective study of these advanced, unresectable HCC patients, although several small series having evaluated prognostic factors in these patients 20,24–30 …”

Section: Introductionmentioning

confidence: 99%

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study

Carr

Buch

Kondragunta

et al. 2008

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Prognostic Index for Survival in Patients After Treatment for Primary Hepatocellular Carcinoma

Cited by 7 publications

References 29 publications

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study

Contact Info

Product

Resources

About